Home › Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA (pembrolizumab) Data
 

Keywords :   


Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA (pembrolizumab) Data

2015-12-08 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, across a range of hematological cancers were presented at the 57th American Society of Hematology (ASH) Annual Meeting. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: add data range growing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.06Atlantic Tropical Weather Outlook
30.06Eastern North Pacific Tropical Weather Outlook
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Public Advisory Number 6A
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Wind Speed Probabilities Number 6
30.06Hurricane Beryl Public Advisory Number 6
More »